Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
Dept of Defense · Defense Logistics Agency · Sol. SPE2D222R0117
No deadlineClosed
This contract has been awarded
Awarded to Golden State Medical Supply Inc for $17.6M on Feb 15, 2023.
Recent DLA contract awards: who won →
These similar contracts are still open:
- Febuxostat TabletsDLA Troop Support wants one national supplier of febuxostat tablets (40 mg and 80 mg, 30-count bottles) for the DoD and VA pharmacy prime vendor programs.
- Latanoprost Ophthalmic Solution (VA-27-00006027)The VA Enterprise Procurement Office plans to buy Latanoprost eye drops (an ophthalmic solution) for VA, DoD, Bureau of Prisons, Indian Health Service and the Federal Health Care…
- Imatinib TabletsThe Department of Veterans Affairs (National Acquisition Center) plans to award one contract for imatinib mesylate tablets, a cancer drug, to supply VA, DoD, Bureau of Prisons,…
- Methylphenidate ERThe Defense Logistics Agency (DLA Troop Support) plans a national requirements contract for Methylphenidate ER tablets (18, 27, 36 and 54 mg, 100-count bottles).
- Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount ProgramThe Defense Health Agency is asking drug manufacturers to quote discounted prices and refunds on 12 newly FDA-approved brand drugs so its Pharmacy and Therapeutics Committee can…
AI summary Beta
No AI summary for this notice yet.
Save it to generate your own AI brief in its bid workspace: a plain-English summary, the red flags, and how well your business fits.
Key facts
- Posted
- Sep 24, 2026
- Notice type
- Award Notice
- Solicitation
- SPE2D222R0117
- Agency
- Dept of Defense · Defense Logistics Agency
- Office
- DLA Troop Support
- NAICS
- 325412
- Product/service code
- 6505
- Business type
- Medical & healthcare
- Place of performance
- Ontario, Canada
- Contracting contact
- Kyle Lewickikyle.lewicki@dla.mil4457370977
Before you respond
Full notice text from SAM.gov
Modification SPE2D223D0007 P00013 No-Cost Settlement Termination for Convenience. Modification SPE2D223D0007 P00012 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026). Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle. Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23. Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027. Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003. Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026. Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract. Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025. Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract. Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract. Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023. Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle